Inogen reported breakeven adjusted earnings per share for the second quarter of 2026, beating the Zacks Consensus Estimate by 17.7% and improving from a loss of 2 cents a year ago. Revenue rose 3% to $95.1 million, slightly above the $95 million consensus, driven by a 14.8% jump in international sales to $41.3 million, while U.S. sales dipped 2.3% to $42.3 million and U.S. rental revenue fell 11.8% to $11.6 million. The company lowered its full-year 2026 revenue guidance to a range of $355 million to $361 million, down from the prior $366 million to $373 million, citing continued U.S. sales channel mix pressure and the timing of international distributor purchases. For the third quarter, Inogen expects revenue in line with the year-ago quarter's $92.4 million. The company ended the quarter with $87.3 million in cash and no debt, and repurchased 1,145,150 shares for $7.5 million during the first half of the year.
Inogen IncInogen cut full-year revenue guidance despite beating Q2 EPS estimates.
The Cooper Companies, Inc
Cardinal Health Inc
West Pharmaceutical Services Inc